A new venture is working on alternatives to a coronavirus COVID-19 vaccine. (Courtesy photo)

A new venture is working on alternatives to a coronavirus COVID-19 vaccine. (Courtesy photo)

San Francisco-based fund supporting COVID-19 treatment trials

CETF hopes existing drugs can help address coronavirus quickly

While scientists are racing to develop new vaccines against COVID-19, others believe the fastest and most effective strategy of developing treatments may lie in repurposing drugs that already proven safe and can be mass produced at a faster rate.

“New drugs take years, and hundreds and millions of dollars to develop,” said Steve Kirsch, founder of San Francisco-based COVID-19 Early Treatment Fund.

Kirsh, an entrepreneur and philanthropist, is hoping to help researchers identify early treatments for people with COVID-19 by establishing CETF in April. It is focused on funding outpatient trials of repurposed drugs where participants do not have to stay overnight at the hospital.

“I have multiple risk factors … if I got the virus, I have a 20 percent chance of dying,” Kirsch said. “I was interested in saving my life in the event I contracted COVID, and also the lives of my family and friends, and other people.”

One trial at the University of California, Los Angeles, approved by CETF will test the effectiveness of the oral drug Favipiravir, an anti-influenza medication. And researchers at Stanford University are conducting the first outpatient clinical trial of Favipiravir in the United States, which does not involve CETF, to assess whether the oral drug can reduce the severity of people’s symptoms and lower transmission rates.

The U.S. Food and Drug Administration has approved the antiviral drug called Remdesivir, originally created as a general antiviral and later tested in patients with the Ebola virus. While the drug has been proven effective in treating hospitalized COVID-19 patients, Remdesivir is too expensive and difficult to administer to a broader population, according to Kirsch. After all, it is administered intravenously through an IV drip.

Another repurposed drug in CETF’s clinical trial pipeline is Interferon Lambda. It has been tested on people with either Hepatitis B or Hepatitis C virus, according to CETF. And the trials of the drug for people with COVID-19 are conducted by a team at Stanford University and researchers at other institutions.

Even though some of the CETF-approved trials are now underway, others such as the UCLA trial of Favipiravir are still pending for funding from CETF.

“We are strapped for cash. We’ve raised only three million. We need 20 million,” Kirsch said. “For $20 million, we will find something that is effective against this virus that is costing us trillions of dollars.”

nchan@sfexaminer.com

Bay Area NewsCoronavirussan francisco news

Just Posted

Cabernet sauvignon grapes sat in a container after being crushed at Smith-Madrone Winery in St. Helena. (Courtesy Smith-Madrone Winery)
San Francisco’s ‘Champagne problems’ — Wine industry suffers supply chain woes

‘Everywhere you turn, things that were easy are no longer easy’

Glasses behind the bar at LUNA in the Mission District on Friday, Oct. 15, 2021. Glassware is just one of the many things restaurants have had trouble keeping in stock as supply chain problems ripple outward. (Kevin N. Hume/The Examiner)
SF restaurants face product shortages and skyrocketing costs

‘The supply chain crisis has impacted us in almost every way imaginable’

A Giants fans hangs his head in disbelief after the Dodgers won the NLDS in a controversial finish to a tight Game 5. (Chris Victorio/Special to The Examiner)
Giants dream season ends at the hands of the Dodgers, 2-1

A masterful game comes down to the bottom of the ninth, and San Francisco came up short

<strong>Workers with Urban Alchemy and the Downtown Streets Team clean at Seventh and Market streets on Oct. 12. <ins>(Kevin N. Hume/The Examiner)</ins> </strong>
<ins></ins>
Why is it so hard to keep San Francisco’s streets clean?

Some blame bureaucracy, others say it’s the residents’ fault

Speaker of the House Nancy Pelosi — seen in Washington, D.C., on Tuesday — touted Congressional Democrats’ infrastructure bill in San Francisco on Thursday. (Stefani Reynolds/The New York Times)
Pelosi touts infrastructure bill as it nears finish line

Climate change, social safety net among major priorities of Democrats’ 10-year funding measure

Most Read